| Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT) (NCT04398849) | University of Adelaide | 2021-03-04 |
| Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study (NCT04239430) | St George's, University of London | 2020-11-26 |
| Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays (NCT04023929) | St George's, University of London | 2020-10-28 |
| Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. (NCT03378258) | Belfast Health and Social Care Trust | 2017-11-09 |
| Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B (NCT03125616) | St George's, University of London | 2017-08-01 |
| South Australian Meningococcal B Vaccine Herd Immunity Study (NCT03089086) | University of Adelaide | 2017-04-01 |
| PRIME Follow up - Quadri Meningo Vacinees (NCT02811120) | Public Health England | 2016-12-01 |
| A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) (NCT02451514) | GlaxoSmithKline | 2015-06-30 |
| Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (NCT02285777) | GlaxoSmithKline | 2014-12-01 |
| Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry (NCT02223637) | GlaxoSmithKline | 2014-09-30 |
| Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. (NCT02173704) | GlaxoSmithKline | 2014-09-11 |
| Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents (NCT02140762) | Novartis Vaccines | 2014-05-01 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. (NCT02141516) | Novartis | 2014-05-01 |
| Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180) (NCT01992536) | Novartis Vaccines | 2013-12-01 |
| Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. (NCT01973218) | Novartis Vaccines | 2013-11-01 |
| Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers (NCT01994629) | Novartis Vaccines | 2013-11-01 |
| Hepatitis B Vaccination in Infants (NCT01896596) | Public Health England | 2013-07-01 |
| Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose (NCT01823536) | Novartis Vaccines | 2013-05-01 |
| A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (NCT01478347) | Novartis Vaccines | 2013-05-01 |
| Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea (NCT01766206) | GlaxoSmithKline | 2013-03-15 |
| Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines (NCT01782066) | Leiden University Medical Center | 2013-01-01 |
| Understanding the Immune Response to Two Different Meningitis Vaccines (NCT01593514) | University of Oxford | 2012-12-01 |
| Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 (NCT01717638) | Novartis Vaccines | 2012-11-01 |
| Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (NCT01725217) | Novartis Vaccines | 2012-11-01 |
| Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. (NCT01682876) | GlaxoSmithKline | 2012-10-07 |
| Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea (NCT01642589) | Sanofi Pasteur, a Sanofi Company | 2012-07-01 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (NCT01466387) | Novartis | 2011-11-01 |
| Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (NCT01453348) | Novartis Vaccines | 2011-10-01 |
| Safety of MenACWY-CRM Vaccination in Adolescents (NCT01452464) | Novartis Vaccines | 2011-09-01 |
| Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers (NCT01434680) | Novartis | 2011-09-01 |
| Safety Surveillance of MenACWY-CRM Vaccine in Children (NCT01452438) | Novartis Vaccines | 2011-09-01 |
| Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children (NCT01430611) | Sanofi Pasteur, a Sanofi Company | 2011-08-01 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years (NCT01423084) | Novartis | 2011-08-01 |
| Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines (NCT01367158) | Novartis Vaccines | 2011-07-01 |
| Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine (NCT01345721) | Novartis Vaccines | 2011-05-01 |
| A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years (NCT01339923) | Novartis Vaccines | 2011-04-01 |
| Testing the Use of Prompts to Increase Adolescent Immunization Rates (NCT01984125) | University of California, Los Angeles | 2011-04-01 |
| A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea (NCT01274897) | Novartis Vaccines | 2010-12-01 |
| Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines (NCT01270503) | Sanofi Pasteur, a Sanofi Company | 2010-12-01 |
| Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life (NCT01214837) | Novartis Vaccines | 2010-10-01 |
| Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 (NCT01148524) | Novartis Vaccines | 2010-08-01 |
| One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age (NCT01139021) | Novartis Vaccines | 2010-06-01 |
| Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine (NCT01026974) | Novartis Vaccines | 2010-02-01 |
| Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine (NCT01027351) | Novartis Vaccines | 2010-01-01 |
| A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months (NCT01000311) | Novartis Vaccines | 2009-11-01 |
| Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 (NCT00944034) | Novartis Vaccines | 2009-07-01 |
| Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers (NCT00847145) | Novartis Vaccines | 2009-02-01 |
| Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules (NCT00661713) | Novartis Vaccines | 2008-06-01 |
| Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months (NCT00601731) | Novartis Vaccines | 2008-02-01 |
| Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults (NCT00560313) | Novartis Vaccines | 2007-07-01 |
| B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants (NCT00488683) | Novartis Vaccines | 2007-07-01 |
| Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants (NCT00433914) | Novartis Vaccines | 2007-02-01 |
| Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age (NCT00329849) | Novartis Vaccines | 2006-05-01 |
| Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years (NCT00329901) | Novartis Vaccines | 2006-04-01 |
| Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents (NCT00297817) | Novartis Vaccines | 2006-02-01 |
| Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine (NCT00254995) | Sanofi Pasteur, a Sanofi Company | 2005-07-01 |